Dapiglutide
Product Specifications
UNSPSC Description
Dapiglutide (ZP7570) is a long-acting glucagon-like peptide-1 receptor 1R (GLP-1R)/Glucagon-like peptide-2 receptor (GLP-2R) dual agonist. Dapiglutide alleviates intestinal dysfunction in a mouse short bowel model and has anti-obesity effects[1][2][3].
Target Antigen
GCGR
Type
Peptides
Related Pathways
GPCR/G Protein
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/dapiglutide.html
Purity
99.40
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
[Dapiglutide]
Molecular Weight
4166.79
References & Citations
[1]Zealand Pharma doses first subject in Phase 1 clinical trial with potential next generation dual-acting peptide therapeutic for short bowel syndrome. 26 June 2019.|[2]Johannes Reiner, et al. Dapiglutide, a novel dual GLP-1 and GLP-2 receptor agonist, attenuates intestinal insufficiency in a murine model of short bowel. JPEN J Parenter Enteral Nutr. 2022 Jul;46(5):1107-1118.|[3]Copenhagen, et al. Anti-obesity Effect of Dapiglutide Alone and in Combination With the Amylin Analog ZP8396 in DIO Rat. obesity. Spring Vol. 30, (Nov 2022): 11-12.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light, under nitrogen)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P3291/Dapiglutide-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P3291/Dapiglutide-SDS-MedChemExpress.pdf
Clinical Information
Phase 2
CAS Number
2296814-85-0
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
66803156 3x1.0μg DNA
RGD1304719 CRISPR All-in-one AAV vector set (with saCas9)(Rat)
Ask
View Details 